News Release

• Revenue was $179.3 million in the third quarter of 2018. (Under ASC 605, net service revenue of $124.0 million increased 25.6% from net service revenue of $98.7 million for the comparable prior-year period, representing a backlog conversion rate of 21.2%.)
• Net new business awards were $227.6 million in the third quarter. (Under ASC 605, net new business awards were $150.1 million in the third quarter, representing an increase of 33.9% from net new business awards of $112.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.21x.)
• GAAP net income was $19.3 million, or $0.52 per diluted share, and net income margin was 10.8% in the third quarter of 2018. (Under ASC 605, third quarter 2018 GAAP net income was $24.0 million, or $0.64 per diluted share, versus GAAP net income of $9.8 million, or $0.25 per diluted share, for the comparable prior-year period. Net income margin was 19.4% and 10.0% for the third quarter of 2018 and 2017, respectively.)
• Adjusted EBITDA was $36.4 million for the third quarter of 2018, resulting in an Adjusted EBITDA margin of 20.3%. (Under ASC 605, Adjusted EBITDA of $42.7 million for the third quarter increased 52.1% from the comparable prior-year period, resulting in an Adjusted EBITDA margin of 34.4%.)
• Adjusted Net Income was $25.0 million, or $0.67 per diluted share, for the third quarter of 2018. (Under ASC 605, Adjusted Net Income of $29.7 million for the third quarter increased 86.8% from the comparable prior-year period. Adjusted Net Income per diluted share of $0.80 for the third quarter of 2018 increased 100.0% from the comparable prior-year period.)

CINCINNATI--(BUSINESS WIRE)--Oct. 29, 2018-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2018.

Third Quarter 2018 Financial Results under ASC 606

Revenue for the three months ended September 30, 2018 was $179.3 million. Backlog as of September 30, 2018 was $1.0 billion and net new business awards were $227.6 million, representing a net book-to-bill ratio of 1.27x for the third quarter of 2018. The Company calculates the net book-to-bill ratio by dividing net new business awards by revenue.

For the third quarter of 2018, total direct costs were $124.0 million, and Adjusted direct costs were $124.8 million. Selling, general and administrative expenses were $18.6 million and Adjusted Selling, general and administrative expenses were $18.5 million for the third quarter 2018.

GAAP net income for the third quarter of 2018 was $19.3 million, or $0.52 per diluted share, which resulted in a net income margin of 10.8%. Adjusted EBITDA for the third quarter of 2018 was $36.4 million, or 20.3% of revenue. Adjusted Net Income was $25.0 million, and Adjusted Net Income per diluted share was $0.67 for the third quarter of 2018.

Third Quarter 2018 Financial Results under ASC 605

Net service revenue for the three months ended September 30, 2018 increased 25.6% to $124.0 million, compared to $98.7 million for the comparable prior-year period. On a constant currency basis, net service revenue for the third quarter of 2018 increased 25.8% compared to the third quarter of 2017.

Backlog as of September 30, 2018 grew 19.4% to $608.7 million from $510.0 million as of September 30, 2017. Net new business awards were $150.1 million, representing a net book-to-bill ratio of 1.21x for the third quarter of 2018, as compared to $112.1 million for the comparable prior-year period.

For the third quarter of 2018, Direct service costs, excluding depreciation and amortization, were $62.5 million, compared to $53.1 million in the third quarter of 2017. Adjusted Direct service costs were $63.3 million for the third quarter 2018, compared to $53.9 million in the third quarter of 2017.

Selling, general and administrative expenses were $18.6 million in the third quarter of 2018, compared to $16.6 million in the third quarter of 2017. Adjusted Selling, general and administrative expenses were $18.5 million for the third quarter 2018 versus $16.5 million in the third quarter of 2017.

GAAP net income for the third quarter of 2018 was $24.0 million, or $0.64 per diluted share, versus GAAP net income of $9.8 million, or $0.25 per diluted share, for the third quarter of 2017. This resulted in a net income margin of 19.4% and 10.0% for the third quarter of 2018 and 2017, respectively.

Adjusted EBITDA for the third quarter of 2018 increased 52.1% to $42.7 million, or 34.4% of net service revenue, compared to $28.0 million, or 28.4% of net service revenue, for the comparable prior-year period. On a constant currency basis, Adjusted EBITDA for the third quarter of 2018 increased 50.1% from the third quarter of 2017.

Adjusted Net Income for the third quarter of 2018 increased 86.8% to $29.7 million, compared to $15.9 million for the comparable prior-year period. Adjusted Net Income per diluted share for the third quarter of 2018 was $0.80 compared to Adjusted Net Income per diluted share of $0.40 for the comparable prior-year period.

A reconciliation of the Company’s non-GAAP financial measures, including EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Direct costs, Adjusted Selling, general and administrative expenses, Adjusted Net Income, and Adjusted Net Income per diluted share to the corresponding GAAP measures is provided below.

Balance Sheet and Liquidity

The Company’s Cash and cash equivalents were $22.2 million at September 30, 2018, and the Company generated $52.5 million in cash flow from operating activities during the third quarter of 2018.

Financial Guidance

On January 1, 2018, the Company adopted ASC 606 “Revenue from Contracts with Customers.” For full-year 2018, the Company is providing guidance under ASC 605, excluding the impact of the new accounting standard, for comparability purposes. The Company forecasts 2018 net service revenue in the range of $474.0 million to $479.0 million, representing growth of 22.7% to 23.9% over 2017 net service revenue of $386.5 million. GAAP net income for full year 2018 is forecasted in the range of $79.9 million to $82.1 million. Additionally, full-year 2018 Adjusted EBITDA is expected in the range of $147.0 million to $149.0 million.

Based on forecasted 2018 net service revenue of $474.0 million to $479.0 million and GAAP net income of $79.9 million to $82.1 million, diluted earnings per share (GAAP) is forecasted in the range of $2.16 to $2.22. Adjusted Net Income for 2018 is forecasted in the range of $102.0 million to $104.0 million, compared to Adjusted Net Income of $60.5 million for 2017. Furthermore, Adjusted Net Income per diluted share for 2018 is expected in the range of $2.76 to $2.82 per share.

Conference Call Details

Medpace will host a conference call at 9:00 a.m. ET, Tuesday, October 30, 2018, to discuss its third quarter 2018 results.

To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 2282569.

To access the conference call via webcast, visit the “Investors” section of Medpace’s website at medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

A recording of the call will be available at 12:00 p.m. ET on Tuesday, October 30, 2018 until 12:00 p.m. ET on Tuesday, November 13, 2018. To hear this recording, dial855-859-2056 (domestic) or 404-537-3406 (international) using the passcode 2282569.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,800 people across 36 countries.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our anticipated financial results and effective tax rate used for non-GAAP adjustment purposes. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” “forecast,” “may,” “could,” “likely,” “anticipate,” “project,” “goal,” “objective,” similar expressions, and variations or negatives of these words.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our financial condition, actual results, performance (including share price performance), or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the potential loss, delay or non-renewal of our contracts, or the non-payment by customers for services we have performed; the failure to convert backlog to revenue at our present or historical conversion rate; fluctuation in our results between fiscal quarters and years; decreased operating margins due to increased pricing pressure or other pressures; failure to perform our services in accordance with contractual requirements, government regulations and ethical considerations; the impact of underpricing our contracts, overrunning our cost estimates or failing to receive approval for or experiencing delays with documentation of change orders; our failure to successfully execute our growth strategies; the impact of a failure to retain key executives or other personnel or recruit experienced personnel; the risks associated with our information systems infrastructure, including potential security breaches and other disruptions which could compromise our information; our failure to manage our growth effectively; adverse results from customer or therapeutic area concentration; the risks associated with doing business internationally, including the effects of tariffs and trade wars; the risks associated with the Foreign Corrupt Practices Act and other anti-corruption laws; future net losses; the impact of changes in tax laws and regulations; the risks associated with our intercompany pricing policies; our failure to attract suitable investigators and patients to our clinical trials; the liability risks associated with our research and development services; the risks related to our Phase I clinical services; inadequate insurance coverage for our operations and indemnification obligations; fluctuations in exchange rates; the risks related to our relationships with existing or potential customers who are in competition with each other; our failure to successfully integrate potential future acquisitions; potential impairment of goodwill or other intangible assets; our limited ability to utilize our net operating loss carryforwards or other tax attributes; the risks associated with the use and disposal of hazardous substances and waste; the failure of third parties to provide us critical support services; our limited ability to protect our intellectual property rights; the risks associated with potential future investments in our customers’ business or drugs; general economic conditions in the markets in which we operate, including financial market conditions; the impact of a natural disaster or other catastrophic event; negative outsourcing trends in the biopharmaceutical industry and a reduction in aggregate expenditures and research and development budgets; our inability to compete effectively with other CROs; the impact of healthcare reform; the impact of recent consolidation in the biopharmaceutical industry; failure to comply with federal, state and foreign healthcare laws; the effect of current and proposed laws and regulations regarding the protection of personal data; our potential involvement in costly intellectual property lawsuits; actions by regulatory authorities or customers to limit the scope of or withdraw an approved drug, biologic or medical device from the market; failure to keep pace with rapid technological changes; the impact of industry-wide reputational harm to CROs; the end result of any negotiations between the U.K. government and the EU regarding the terms of the U.K.'s exit from the EU, which could have implications on our research, commercial and general business operations in the U.K. and the EU; changes in U.S. generally accepted accounting principles, including the impact of the changes to the revenue recognition standards; risks related to internal control over financial reporting; our ability to fulfill our debt obligations; the risks associated with incurring additional debt or undertaking additional debt obligations; the effect of covenant restrictions under our debt agreements on our ability to operate our business; our inability to generate sufficient cash to service all of our indebtedness; fluctuations in interest rates; and our dependence on our lenders, which may not be able to fund borrowings under the credit commitments, and our inability to borrow.

These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 27, 2018, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Non-GAAP Financial Measures

Certain financial measures presented in this press release, such as EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Direct costs, Adjusted Selling, general and administrative expenses, Adjusted Net Income, and Adjusted Net Income per diluted share, are not recognized under generally accepted accounting principles in the United States of America, or U.S. GAAP. Management uses EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Direct costs, Adjusted Selling, general and administrative expenses, Adjusted Net Income, and Adjusted Net Income per diluted share or comparable metrics as a measurement used in evaluating our operating performance on a consistent basis, as a consideration to assess incentive compensation for our employees, for planning purposes, including the preparation of our internal annual operating budget, and to evaluate the performance and effectiveness of our operational strategies.

EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Direct costs, Adjusted Selling, general and administrative expenses, Adjusted Net Income, and Adjusted Net Income per diluted share have important limitations as analytical tools and you should not consider them in isolation, or as a substitute for, analysis of our results as reported under U.S. GAAP. See the condensed consolidated financial statements included elsewhere in this release for our U.S. GAAP results. Additionally, for reconciliations of EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Direct costs, Adjusted Selling, general and administrative expenses, Adjusted Net Income, Adjusted Net Income per diluted share to our closest reported U.S. GAAP measures, refer to the appendix of this press release.

EBITDA, Adjusted EBITDA and Adjusted EBITDA margin

We believe that EBITDA, Adjusted EBITDA, and Adjusted EBITDA margin are useful to provide additional information to investors about certain material non-cash and non-recurring items. While we believe these financial measures are commonly used by investors to evaluate our performance and that of our competitors, because not all companies use identical calculations, this presentation of EBITDA, Adjusted EBITDA and Adjusted EBITDA margin may not be comparable to other similarly titled measures of other companies and should not be considered as an alternative to performance measures derived in accordance with U.S. GAAP. EBITDA is calculated as net income (loss) attributable to Medpace Holdings, Inc. before income tax expense, interest expense, net, depreciation and amortization with Adjusted EBITDA being further adjusted for unusual and other items. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by Service revenue, net for each period. Our presentation of EBITDA, Adjusted EBITDA and Adjusted EBITDA margin should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

Adjusted Net Income and Adjusted Net Income per diluted share

Adjusted Net Income measures our operating performance by adjusting net income (loss) attributable to Medpace Holdings, Inc. to include cash expenditures related to rental payments on leases classified for accounting purposes as deemed landlord liabilities, and exclude amortization expense, certain stock based compensation award non-cash expenses, certain litigation expenses, deferred financing fees and certain other non-recurring items. Adjusted Net Income per diluted share measures Adjusted Net Income on a per diluted share basis. Management uses these measures to evaluate our core operating results as it excludes certain items whose fluctuations from period-to-period do not necessarily correspond to changes in the core operations of the business, but includes certain items such as depreciation, interest expense and tax expense, which are otherwise excluded from Adjusted EBITDA. We believe the presentation of Adjusted Net Income and Adjusted Net Income per diluted share enhances our investors’ overall understanding of the financial performance. You should not consider Adjusted Net Income or Adjusted Net Income per diluted share as an alternative to Net income (loss) or Net income per diluted share attributable to Medpace Holdings Inc., determined in accordance with U.S. GAAP, as an indicator of operating performance.

Adjusted Direct costs and Adjusted Selling, general and administrative expenses

Adjusted Direct costs and Adjusted Selling, general and administrative expenses are useful to provide information to investors to evaluate core operating expenses as they exclude certain items whose fluctuations from period-to-period do not necessarily correspond to changes in the core operations of the business, but includes certain items such as certain lease payments which are otherwise excluded from core operating expenses. We believe that reporting these metrics enhance our investors’ overall understanding of our core recurring operating expenses. You should not consider Adjusted Direct costs and Adjusted Selling, general and administrative expenses as an alternative to Direct costs, excluding depreciation and amortization and Selling, general and administrative expenses, determined in accordance with U.S. GAAP, as an indicator of operating performance.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181029005657/en/

Source: Medpace Holdings, Inc.

Medpace Holdings, Inc.
Media Contact:
Julie Hopkins, 513-579-9911 x12627
j.hopkins@medpace.com
or
Investor Contact:
investor@medpace.com